How to Test Human-Specific Combination Immunotherapies In Vivo

Por um escritor misterioso

Last updated 15 abril 2025

How to Test Human-Specific Combination Immunotherapies In Vivo

Learn how to evaluate combinations of human-specific checkpoint inhibitors in vivo, with double knock-in humanized drug target mouse models.

Immunocompetent cancer-on-chip models to assess immuno-oncology therapy - ScienceDirect

Immunotherapy and targeted therapy combinations in metastatic breast cancer - The Lancet Oncology

The next wave of cellular immunotherapies in pancreatic cancer - ScienceDirect

Frontiers Humanized Mice as a Valuable Pre-Clinical Model for Cancer Immunotherapy Research

Cell-penetrating peptides enhance peptide vaccine accumulation and persistence in lymph nodes to drive immunogenicity

Beginners Guide to PBMC Humanized Tumor Models

Biodegradable lipophilic polymeric mRNA nanoparticles for ligand-free targeting of splenic dendritic cells for cancer vaccination

The oncolytic Newcastle disease virus as an effective immunotherapeutic strategy against glioblastoma in: Neurosurgical Focus Volume 50 Issue 2 (2021) Journals

Enhancing Combined Immunotherapy and Radiotherapy through Nanomedicine

Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy

STING activation promotes robust immune response and NK cell–mediated tumor regression in glioblastoma models

Frontiers Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant

Cancer vaccines: the next immunotherapy frontier

Recomendado para você